Study to Assess the Efficacy and Safety of LIB003 in HeFH Patients on Oral Lipid Therapy Needing Further LDL-C Reduction
Condition: Heterozygous Familial Hypercholesterolemia · Sponsor: LIB Therapeutics LLC
About this study
This study is to assess LDL-C reductions at Week 24 and the mean of Weeks 22 and 24 with monthly Q4W (≤31 days) dosing of LIB003 300 mg administered subcutaneously (SC) compared to placebo in patients 18 years or older with Heterozygous FH on stable diet and oral LDL-C lowering drug therapy.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (7)
| Metabolic & Atherosclerosis Research Center (MARC) | Cincinnati, Ohio, United States | — |
| Department of Medicine, Hadassah University Hospital | Jerusalem, Israel | — |
| Rabin Medical Center, Beilinson Hospital, | Petah Tikva, Israel | — |
| Lipid Clinic, Oslo University Hospital | Oslo, Norway | — |
| Carbohydrate and Lipid Metabolism Research Unit | Johannesburg, Gauteng, South Africa | — |
| Division of Lipidology, Department of Medicine University of Cape Town | Cape Town, Western Province, South Africa | — |
| Ege University Medical School | Izmir, Bornova, Turkey (Türkiye) | — |
Sponsor or site team? See the site landscape for this trial — listed sites, countries, and recruiting-density context.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04797104